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Edited by Laszlo NagyAbstract Unregulated uptake of oxidized low-density lipopro-
teins (ox-LDL) via macrophage scavenger receptors (SRs) such
as lectin-like ox-LDL receptor-1 (LOX-1) is a key event in
atherosclerosis. In this study, we examined the eﬀects of ﬁve
selected food phytochemicals on 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced LOX-1 mRNA expression in THP-1 hu-
man monocyte-like cells. Nobiletin, a citrus polymethoxylated
ﬂavone, markedly reduced it in dose- and time-dependent man-
ners. It also suppressed the phosphorylation of extracellular sig-
nal-regulated protein kinase (ERK) 1/2, c-Jun NH2-terminal
kinase (JNK) 1/2, and c-Jun (Ser-63), thereby inhibiting the
transcriptional activity of activator protein-1. Further nobiletin
attenuated expression of SR-A, SR-PSOX, CD36, and CD68,
but not CLA-1, mRNA, leading to the blockade of DiI-acLDL
uptake. Together, our results suggest that nobiletin is a promis-
ing phytochemical for regulating atherosclerosis with reasonable
action mechanisms.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nobiletin1. Introduction
Atherosclerosis is now understood as a disease characterized
by inﬂammation that results in a host of complications, includ-
ing ischemia, acute coronary syndromes (unstable angina pec-
toris and myocardial infarction), and stroke. There is also
consistent evidence that oxidized low-density lipoprotein (ox-
LDL) is a key factor in the initiation and progression of theAbbreviations: ACA, 10-acetoxychavicol acetate; CLA-1, CD36 and
LIMPII analogous-1; DiI, 1,1 0-dioctadecyl-3,3,3 0,3 0-tetramethylindo-
carbocyanine; DMSO, dimethyl sulfoxide; EGCG, ()-epigallocate-
chin-3-gallate; ERK, extracellular signal-regulated protein kinase;
FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate-dehy-
drogenase; IL, interleukin; LDL, low-density lipoprotein; LOX-1,
lectin-like ox-LDL receptor-1; MAPK, mitogen-activated protein ki-
nase; MMP, matrix metalloproteinase; ox-LDL, oxidized low-density
lipoprotein; PBS, phosphate-buﬀered saline; PPARc, peroxisome
proliferator-activated receptor-gamma; RT-PCR, reverse transcrip-
tion-polymerase chain reaction; SR, scavenger receptor; SR-PSOX, SR
for phosphatidylserine and ox-LDL; TNF-a, tumor necrosis factor-a;
TPA, 12-O-tetradecanoylphorbol-13-acetate
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doi:10.1016/j.febslet.2006.04.077pathology of the disease [1–3]. Ox-LDL has diverse biological
eﬀects, including the expression of pro-inﬂammatory cytokines
and adhesion molecules in arterial wall cells for accelerating
atherogenesis [4], while it is also a chemoattractant for mono-
cytes [5] and cytotoxic toward endothelial cells in culture [6].
After being recruited to subendothelial sites, monocytes diﬀer-
entiate into macrophages and express several distinct scaven-
ger receptors (SRs), which mediate the endocytic uptake of
ox-LDL. Further, macrophages are excessively and irrevers-
ibly loaded with ox-LDL, and then converted into foam cells
because of the lack of a feedback inhibition mechanism for
ox-LDL incorporation [1,7,8].
Thus far, SR-A (class A SR), CD36 and LIMPII analo-
gous-1 (CLA-1); human orthologue of SR-BI and CD36
(class B SR), CD68 (class D SR), lectin-like oxidized LDL
receptor-1 (LOX-1, class E SR), and SR for phosphatidylser-
ine and ox-LDL (SR-PSOX or CXCL16, class G SR) have
been shown to be responsible for cellular ox-LDL uptake
[9]. It is of importance to note that ox-LDL increases the
expression of those SRs, resulting in the enhancement of
foam cell formation. The expression of SRs is induced by tu-
mor necrosis factor-a (TNF-a), 12-O-tetradecanoylphorbol-
13-acetate (TPA), and other factors [10,11], which suggests
that the in vivo expression of SRs may be dynamically reg-
ulated by inﬂammatory and ﬂuid mechanical stimuli. The
importance of expression or repression of SRs in atheroscle-
rosis has been demonstrated using transgenic and knockout
mice. For example, SR-A knockout mice showed a signiﬁ-
cant decrease in atherosclerotic lesions as compared to apo-
lipoprotein E knockout (apoE/) [12] and LDL receptor
knockout (LDLR/) mouse models [13]. In addition, Feb-
braio et al. crossed CD36/ mice with apoE/ mice and
reported a 70% reduction in atherosclerotic lesion size in ani-
mals fed a high-fat diet [14]. These ﬁndings suggest that the
deletion or repression of SRs may lead to a predictable de-
crease in ox-LDL uptake and a resulting decrease in patho-
physiological lesion formation, though a contradictory
ﬁnding was recently presented [15].
Interestingly, the expressions of SRs were decreased by
natural and synthetic peroxisome proliferator-activated
receptor-gamma (PPARc) ligands [16]. In addition, statins,
which inhibit the key enzyme in cholesterol biosynthesis,
have also been reported to downregulate those SRs [17],
while aspirin inhibited ox-LDL-mediated LOX-1 expression
[18]. Further, macrophages from mice given ﬁsh oil had a
low level of expression of SR-A [19], while a-tocopherolblished by Elsevier B.V. All rights reserved.
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[20] and monocyte-derived macrophages [21]. Along a simi-
lar line, Teupser et al. showed that a- and b-tocopherol
downregulate SR-A activity in rabbit peritoneal macro-
phages [22].
In the present study, we investigated the suppressive eﬀects
of ﬁve selected food phytochemicals on TPA-induced LOX-1
expression in a human acute monocytic leukemia cell line,
THP-1, to extend our knowledge of agents that have physio-
logical potentials for the regulation of SR expression. In our
report, we also address the underlying molecular mechanisms
of those eﬀects.2. Materials and methods
2.1. Materials
Roswell Park Memorial Institute (RPMI) 1640 medium was pur-
chased from Gibco BRL (Grand Island, NY) and fetal bovine serum
(FBS) came from Invitrogen (Carlsbad, CA). Oligonucleotide prim-
ers were synthesized by Proligo (Kyoto, Japan). A QIAshredder
and RNeasy Mini Kit were purchased from Qiagen (Hilden, Ger-
many), and an RNA PCR Kit (ver. 2.1, AMV) from TaKaRa Bio
(Shiga, Japan). pRL-TK (containing the Renilla luciferase gene)
and a Dual-Luciferase Reporter Assay System were purchased from
Promega (Madison, WI). Lipofectamine was purchased from Invit-
rogen. A Nuclear/Cytosol Fractionation Kit was purchased from
BioVision (Mountain View, CA). Antibodies were purchased from
the following sources: rabbit anti-phospho-p38 mitogen-activated
protein kinase (MAPK), rabbit anti-p38 MAPK, rabbit anti-phos-
pho-JNK1/2, rabbit-anti-JNK1/2, rabbit anti-phospho-ERK1/2, rab-
bit anti-ERK1/2, rabbit anti-phospho-c-Jun (Ser-63), rabbit anti-
phospho-c-Jun (Ser-73), rabbit anti-c-Jun, and rabbit antibody
horseradish peroxidase-linked IgG antibodies came from Cell Signal-
ing Technology (Beverly, MA); mouse anti-c-Fos and goat anti-b-ac-
tin antibodies came from Santa Cruz Biotechnology (Santa Cruz,
CA); and horseradish peroxidase-conjugated anti-mouse IgG, and
anti-goat IgG came from Dako (Glostrup, Denmark). PD98059,
SB203580, and SP600125 were from Calbiochem (La Jolla, CA).
Acetylated low-density lipoprotein labeled with 1,1 0-dioctadecyl-
3,3,3 0,3 0-tetramethylindo-carbocyanine (DiI) was obtained from Bio-
medical Technologies, Inc. (Stoughton, MA). All other chemicals
were purchased from Wako Pure Chemicals (Osaka, Japan) unless
speciﬁed otherwise.
2.2. Cell culture
Human monocyte-derived THP-1 cells (American Type Culture Col-
lection, Manassas, VA) were maintained in RPMI 1640 medium sup-
plemented with 10% FBS, 100 ng/mL of streptomycin, 100 U/mL of
penicillin, and 300 ng/mL of L-glutamine. The cells were incubated un-
der a humidiﬁed atmosphere of 95% O2 and 5% CO2 at 37 C.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
Cell suspensions were prepared at a concentration of
1.5 · 106 cells/1 mL (RPMI medium with FBS 10%), then incubated
in 12-well plates for 30 min with each test sample at the speciﬁed
concentrations, or with the vehicle (0.5% dimethyl sulfoxide;
DMSO, v/v), followed by stimulation with TPA (30 nM) for the
designated periods of time. The concentration of each agent used
in the bioassays was set to be non-lethal maximum one, which
was determined by preliminary experiments (data not shown). Total
RNA was extracted using a QIAshredder, RNase-free DNase sets,
and an RNeasy Mini Kit. A glyceraldehyde-3-phosphate-dehydro-
genase (GAPDH) transcript served as the internal control. cDNA
was synthesized using 1 lg of total RNA and an RNA PCR Kit
(AMV). PCR ampliﬁcation was performed using a thermal cycler
(PTC-100, MJ Research, Watertown, MA) and conducted with
0.05 lM of each sense and antisense primer. Primer sequences
and PCR conditions (denaturation, annealing, and primer extension
time and temperature) are listed in Table 1. PCR products were
subjected to electrophoresis through 3% agarose gels and stainedwith SYBR Gold. The signal intensities of the bands with ex-
pected sizes were quantiﬁed by NIH Image and compared with that
of the internal standard GAPDH ampliﬁed under identical
conditions.
2.4. Reporter assay
Cells were transfected with 4 lg of AP-1 promoter-luciferase con-
structs with the herpes simplex thymidine kinase driven Renilla lucifer-
ase reporter (pRL-TK) plasmid (Promega) using lipofectamine. Cells
were incubated at a concentration of 2 · 106 cells/mL in Opti-MEM
I medium containing the transfection mixture for 12 h at 37 C. After
transfection, the transfection reagent was replaced with RPMI medium
containing 10% FBS for 12 h. Cells were plated in 24-well plates and
treated with nobiletin (0–100 lM) for 30 min then stimulated with
TPA (30 nM) for 48 h. pRL-TK was used in the co-transfection exper-
iments to compare the transfection eﬃciencies. Fireﬂy and Renilla
luciferase were measured using the Dual-Luciferase Reporter Assay
System (Promega), according to the manufacturer’s protocol. Brieﬂy,
cells were washed with phosphate-buﬀered saline (PBS) and lysed with
passive lysis buﬀer (100 ll/well). The assays for ﬁreﬂy luciferase and
Renilla luciferase activities were performed sequentially in a single
reaction tube using a 20 ll aliquot of each cell lysate. The cell lysates
were mixed with luciferase assay reagent II and ﬁreﬂy luminescence
was measured using a luminometer with dual automatic injector (Lu-
mat LB9507) (Perkin–Elmer, Boston, MA). Next, the samples were
mixed with Stop and Glo reagent and Renilla luciferase activity was
determined as an internal control. Relative luciferase activity was cal-
culated as the ratio of ﬁreﬂy luciferase activity to Renilla luciferase
activity.
2.5. Western blotting
Cells (5 · 106 cells/3 mL RPMI medium with 10% FBS in a 60-
mm dish) were incubated for 30 min with nobiletin (100 lM) or
the vehicle (0.5% DMSO, v/v), then stimulated with TPA
(30 nM) and collected after 0, 2 and 6 h. The concentration of
each agent was determined based on previous cytotoxic experi-
ments (data not shown). Cells were fractionated using a Nucle-
ar/Cytosol Fractionation Kit, with protease and phosphatase
inhibitor cocktails (TaKaRa Bio), according to the recommenda-
tions of the supplier. The protein concentration in the cytosol
fraction was determined using a DC protein assay (Bio-Rad Lab-
oratories, Kyoto, Japan), with c-globulin used as the standard.
Denatured proteins (80 lg) were separated using SDS–polyacryl-
amide gel electrophoresis on a 10% polyacrylamide gel and trans-
ferred onto Immobilon-P Transfer Membranes (Millipore, Bedford,
MA). After blocking overnight at 4 C in Block Ace (Dainippon
Pharmaceutical, Osaka, Japan), the membranes were ﬁrst incu-
bated with each antibody at a dilution of 1:1000 [goat anti-b-ac-
tin, rabbit anti-phospho-ERK1/2, rabbit anti-ERK1/2, rabbit anti-
phospho-p38 MAPK, rabbit anti-p38 MAPK, rabbit anti-phospho-
JNK1/2, rabbit anti-JNK1/2, rabbit anti-phospho-c-Jun (Ser-73),
rabbit anti-phospho-c-Jun (Ser-63), rabbit anti-c-Jun, and mouse
anti-c-Fos (1:500 dilution)]. The second incubation was performed
with horseradish peroxidase-conjugated secondary anti-rabbit IgG,
anti-mouse IgG, or anti-goat IgG (1:1000 dilution each). The blots
were developed using ECL Western blotting detection reagent
(Amersham Biosciences, Buckinghamshire, UK) and the intensity
of each band was analyzed using NIH Image. Relative levels of
each protein were corrected by employing b-actin as the internal
standard.
2.6. Cellular uptake of DiI-acLDL
THP-1 cells were cultured on chamber slides (1 · 105 cells/0.2 mL
RPMI medium with FBS 10%) and incubated for 30 min with the
Nobiletin (100 lM) or the vehicle (0.5% DMSO, v/v). After being stim-
ulated with TPA (30 nM), the cells were incubated at 37 C for 24 h.
After removal of the media, the cells were mounted in RPMI medium
containing DiI-acLDL (10 lg/mL) and incubated at 37 C for 4 h. The
media was removed and the cells were washed three times with PBS,
then ﬁxed with 4% paraformaldehyde for 20 min at room temperature,
followed by washing three times with distilled water at room tempera-
ture. Coverslips were inverted over a drop of 80% PBS in glycerol prior
to viewing. DiI-acLDL uptake was observed with a ﬂuorescence
microscope UFX-35 A (Nikon, Tokyo).
Table 1
List of primer sequences for RT-PCR
Gene Primer Sequence (50–3 0) Product size (bp)
LOX-1a Forward ACTCTCCATggTggTgCCTgg 251
Reverse CATTCAgCTTCCgAgCAAggg
SR-Ab Forward gCAgTTCTCATCCCTCTCATTggA 335
Reverse ATTCCCATgTCCCTgTggACTgAg
CD36c Forward gAgACCTgCTTATCCAgAAgAC 510
Reverse gACCAACTgTggTAgTAACAgg
CLA-1d Forward TgATgATggAgAATAAgCCCAT 696
Reverse TgACCgggTggATgTCCAggAAC
CD68e Forward gCCACTCACAgTCCTgCCACC 426
Reverse ggACACATTgTACTCCACCgCC
SR-PSOXf Forward TACACgAggTTCCAgCTCCT 154
Reverse gggggCTggTAggAAgTAAA
CD11bg Forward TCggCggATgAAggAgTTTg 756
Reverse CTTTgCACCCggTTCCgTAAg
CD18h Forward TCgTggACAAgACCgTgCTgC 421
Reverse CTACTggTCACCgCgAAgATCg
GAPDHi Forward gCACCACCAACTgCTTAgCAC 636
Reverse gTCTgAgTgTggCAgggACTC
a40 s denaturation at 96 C, 30 s of annealing at 60 C, and 90 s of primer extension at 72 C.
b–d40 s at 96 C, 30 s at 55 C, and 90 s at 72 C.
e40 s at 96 C, 30 s at 62 C, and 90 s at 72 C.
f,i30 s at 95 C, 60 s at 58 C, and 60 s at 72 C.
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Each experiment was performed at least three times and data are
shown as the means ± standard deviation (S.D.) where applicable. Sta-
tistically signiﬁcant diﬀerences between groups in each assay were
determined using a Student’s t-test (two-sided).3. Results
3.1. Eﬀects of selected food phytochemicals on TPA-induced
LOX-1 mRNA expression in THP-1 cells
The food phytochemicals used in the present study were
selected based on their pronounced anti-inﬂammatory prop-
erties shown in in vitro and in vivo studies reported previ-
ously [23–26]. In order to examine their eﬀects on LOX-1
mRNA expression, THP-1 human monocytic cells were
pre-treated with each of the ﬁve tested food phytochemicals
[1 0-acetoxychavicol acetate (ACA) at 20 lM, auraptene at
100 lM, nobiletin at 100 lM, ()-epigallocatechin-3-gallate
(EGCG) at 100 lM, resveratrol at 20 lM] or the vehicle, fol-
lowed by TPA exposure for 24 h. As shown in Fig. 1A, the
vehicle-treated THP-1 cells scarcely expressed LOX-1
mRNA, as detected by RT-PCR, whereas treatment with
TPA highly induced it by 7.3-fold, while nobiletin attenuated
it by 75%. In contrast, ACA, auraptene, EGCG, and resve-
ratrol increased the expression by 1.7- to 3.0-fold.3.2. Concentration- and time-dependency of nobiletin on LOX-1
mRNA expression suppression
As shown in Fig. 1B, TPA-treated THP-1 cells increased
LOX-1 mRNA levels in a time-dependent fashion from 6 to
24 h. Pretreatment with nobiletin (0.8–100 lM) for 24 h
markedly decreased TPA-induced LOX-1 mRNA in a concen-
tration-dependent manner, with the 50% inhibition concentra-
tion found to be 2.9 lM.
3.3. Nobiletin inhibited AP-1 transactivation
The expression of LOX-1 is regulated by several transcrip-
tional factors, including AP-1 [27]. To evaluate the mechanism
by which nobiletin downregulates the expression of LOX-1, we
examined its inhibitory eﬀects on TPA-induced activation of
AP-1. TPA-treatment led to a sevenfold increase in AP-1 tran-
scription activity (Fig. 1C), while a concentration-dependent
suppression ranging from 35% to 66% was seen when the cells
were pre-treated with nobiletin in a concentration range of 4–
100 lM.
3.4. Nobiletin inhibited MAPK activation
Activation of the MAPK cascade is well known to contrib-
ute to AP-1 transactivation. Therefore, we pre-treated THP-1
cells with nobiletin (100 lM) or the vehicle for 30 min and then
stimulated them with TPA for 0, 2, and 6 h. The cytosolic pro-
Fig. 1. (A) Eﬀects of food phytochemicals on TPA-induced LOX-1
mRNA expression in THP-1 cells. Cells (1.5 · 106 cells/mL) were
incubated separately for 30 min with each of ﬁve food phytochemicals
[ACA (20 lM), nobiletin (100 lM), auraptene (100 lM), EGCG
(100 lM), and resveratrol (20 lM)] or the vehicle, followed by stimu-
lation with TPA (30 nM) for 24 h. At the end of the incubation period,
the cells were lysed and LOX-1 mRNA was analyzed by RT-PCR as
described in Section 2. LOX-1 mRNA levels were normalized to the
levels of GAPDH mRNA. aP < 0.005, bP < 0.05 versus blank.
cP < 0.005, dP < 0.01 versus TPA. Data are expressed as the
means ± S.D. of three independent experiments. (B) Dose-dependent
eﬀect of nobiletin on TPA induced LOX-1 mRNA expression in THP-1
cells. Cells (1.5 · 106 cells/mL) were cultured with the vehicle for 30 min
followed by stimulation with TPA (30 nM) for 6, 12, or 24 h then
cultured with nobiletin at a concentration of 0.8, 4, 20, or 100 lM for
30 min followed by stimulationwithTPA (30 nM) for 24 h.At the end of
the incubation period, the cells were lysed and LOX-1 mRNA was
analyzed by RT-PCR. LOX-1 mRNA levels were normalized to the
levels of GAPDH mRNA. Data are expressed as the means ± S.D. of
three experiments. aP < 0.01, bP < 0.001 versus blank. cP < 0.001 versus
TPA. (C) THP-1 cells were transfected with AP-1 promoter-luciferase
constructs with the pRL-TK plasmid using lipofectamine for 12 h at
37 C. Next, the transfection reagent was replaced by RPMI medium
containing 10%FBS and the cells were incubated for an additional 12 h.
The cells were plated in 24-well plates and treated with nobiletin (0.8–
100 lM) or the vehicle for 30 min then stimulated with TPA (30 nM) for
48 h. Fireﬂy and Renilla luciferase activities were determined using a
Dual-Luciferase Reporter Assay System (Promega), according to the
manufacturer’s protocol. Relative luciferase activity was calculated as
the ratio of ﬁreﬂy luciferase activity to that of Renilla luciferase.
*P < 0.005, **P < 0.001 versus TPA.
Fig. 2. Nobiletin inhibits MAPK activation. (A) Cells (5 · 106 cells/
3 mL) were incubated for 30 min with nobiletin (100 lM) or the
vehicle, then stimulated with TPA (30 nM) and collected after 0, 2, and
6 h. The cells were fractionated into cytosolic fractions as described in
Section 2. Each protein in the cytosolic fraction was subjected to
Western blotting with antibodies for phospho-ERK1/2, phospho-
JNK1/2, phospho-p38, phospho-c-Jun (Ser-63), phospho-c-Jun (Ser-
73), c-Fos, and b-actin. Three independent experiments were per-
formed, with representative results shown. (B) Pharmacological eﬀects
toward TPA-induced LOX-1 gene expression. THP-1 cells were pre-
treated separately with each of the speciﬁc inhibitors [SB, SB203580
(50 lM); SP, SP600125 (20 lM); PD, PD98059 (100 lM)] for 30 min
before exposure to TPA (30 nM) for 24 h. At the end of the incubation
period, the cells were lysed and LOX-1 mRNA was analyzed by RT-
PCR. LOX-1 mRNA levels were normalized to the levels of GAPDH
mRNA. Data are expressed as the means ± S.D. of three experiments.
aP < 0.05 versus blank, bP < 0.005 versus TPA.
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detect both inactive and activated forms of p38 MAPK, JNK1/
2, and ERK1/2, using speciﬁc antibodies. As shown in Fig. 2A,following TPA treatment, those kinases were markedly and
transiently phosphorylated after 2 h, whereas nobiletin
blocked the TPA-enhanced activation of ERK1/2 and JNK1/
2, but not that of p38 MAPK. In addition, the ﬂavonoid sig-
niﬁcantly reduced c-Jun (Ser-63, but not Ser-73) phosphoryla-
tion, while c-Fos expression was not aﬀected. The expression
levels of the inactive forms of MAPKs were not signiﬁcantly
changed (data not shown).
3.5. Pharmacological eﬀects on TPA-induced LOX-1 gene
expression
To identify the signaling pathways involved in TPA-induced
LOX-1 mRNA expression, THP-1 cells were pre-treated with
each of the speciﬁc inhibitors for 30 min before exposure to
TPA for 12 h. As shown in Fig. 2B, pretreatment with
A. Eguchi et al. / FEBS Letters 580 (2006) 3321–3328 3325SB203580 (p38 MAPK inhibitor, 50 lM), SP600125 (JNK1/2
inhibitor, 20 lM), or PD98059 (MEK1/2 inhibitor, 100 lM)
signiﬁcantly suppressed TPA-induced LOX-1 mRNA expres-
sion in a range of 62–92%.
3.6. Eﬀects toward other SRs and adhesion molecules expression
Next, we examined the eﬀects of nobiletin on the mRNA
expression of other SRs (SR-A, CD36, CD68, SR-PSOX,
and CLA-1) as well as adhesion molecules (CD11b and
CD18) using RT-PCR. THP-1 cells were pre-treated with nobi-
letin at 100 lM or the vehicle, followed by TPA exposure for
24 h. As shown in Figs. 3A and B, cells not treated with
TPA expressed scant levels of SR-A, SR-PSOX, CD11b, and
CD18 mRNA, while those were signiﬁcantly upregulated with
TPA treatment. In addition, CD36, CD68, and CLA-1 mRNA
was highly expressed in a constitutive manner in non-treated
THP-1 cells and CD68 mRNA expression was upregulated
twofold after TPA exposure. Nobiletin abolished the mRNA
expression of SR-A, SR-PSOX, CD36, CD11b, and CD18,
while that of CD68 was decreased to the basal level.
3.7. Nobiletin inhibited DiI-acLDL uptake
The above results led us to examine the eﬀect of nobiletin on
cellular uptake of modiﬁed LDL. DiI-acLDL is known to be
bound to and/or taken up via type A scavenger receptors.
THP-1 cells were pre-treated with 100 lM of nobiletin or the
vehicle for 30 min and then stimulated with TPA for 24 h.
Next, the cells were exposed to DiI-acLDL for 4 h at 37 C.Fig. 3. Suppressive eﬀects of nobiletin on the expression of several
diﬀerent SRs and adhesion molecules. The cells (1.5 · 106 cells/ml)
were incubated with 100 lM of nobiletin or the vehicle for 30 min
followed by stimulation with TPA (30 nM) for 24 h. mRNA from each
sample was quantiﬁed by RT-PCR, using GAPDH as the standard,
described in Section 2. (A) Three independent experiments were
performed, with representative data shown. (B) Each bar represents
the mean ± S.D. #P < 0.05, ##P < 0.005, ###P < 0.001 versus blank.
*P < 0.05, **P < 0.005, ***P < 0.001 versus TPA.
Fig. 4. Suppressive eﬀects of nobiletin on uptake of DiI-acLDL. (A)
THP-1 cells (2.5 · 105 cells/ml) were incubated with nobiletin (100 lM)
or the vehicle for 30 min and stimulated with TPA (30 nM) for 24 h at
37 C. Then, the cells were washed three times with PBS and incubated
with DiI-acLDL (10 lg/ml) for 4 h at 37 C. As a negative control, cells
were incubated without DiI-acLDL. DiI-acLDL uptake was assessed
by ﬂuorescence photomicroscopy. The experiments were repeated
three times independently, with one representative result for each
shown. (a) Negative control, (b) blank, (c) TPA, (d) nobiletin + TPA.
Approximately 100 cells are shown in each photograph. (B) Data are
expressed as the means ± S.D. (n = 3). aP < 0.005 versus blank.
bP < 0.005 versus TPA.No DiI-acLDL uptake by undiﬀerentiated THP-1 cells was ob-
served, whereas TPA treatment led to an increased uptake
(Fig. 4A), which was abolished by nobiletin.4. Discussion
Macrophages have a central role as eﬀector cells at sites of
chronic inﬂammation, such as those associated with athero-
sclerotic plaque. The expression of SRs is upregulated during
the diﬀerentiation of monocytes into macrophages, which is
a key event in the process of atherosclerosis. SRs excessively
uptake ox-LDL through SRs, leading to their conversion
into foam cells [1,7,8]. They are known to be regulated by
TNF-a, TPA, and ox-LDL [10,11], suggesting that SRs
expression in vivo may be dynamically regulated by inﬂam-
matory and ﬂuid mechanical stimuli. Several studies have
also shown that targeted deletion of either SR-A or CD36
in hyperlipidemic mouse models leads to a reduction in ath-
erosclerotic lesions [12–14]. Similarly, Kunjathoor et al. re-
ported that macrophages lacking both SR-A and CD36
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graded ox-LDL and acLDL [28]. Those ﬁndings suggest that
deletion or repression of SRs may predictably decrease ox-
LDL uptake and thereby reduce pathophysiological lesion
formation. However, there are only a few studies regarding
the suppressive eﬀects of food factors on SRs expression
[19–22]. Our results showed that the ﬁve selected food phyto-
chemicals had eﬀects on TPA-induced SRs expression in
THP-1 cells and elucidated some of the underlying molecular
mechanisms.
Nobiletin, a polymethoxylated ﬂavone found speciﬁcally in
citrus fruits [29], is believed to be a promising anti-inﬂamma-
tory and anti-tumor promoting agent [23,30–33]. We previ-
ously reported that nobiletin acts as a dual inhibitor of
superoxide and nitric oxide generation in inﬂammatory leuko-
cytes, and also showed its suppressive eﬀects toward the for-
mation of inﬂammatory mediators and tumor promotion in
mouse skin [23,31]. Further, nobiletin has been found to sup-
press the induction of matrix metalloproteinase (MMP)-7
[32] and MMP-9, as well as the release of prostaglandin E2
in rabbit synovial ﬁbroblasts [33]. In addition, Lin et al. re-
ported that nobiletin suppressed the expression of proinﬂam-
matory cytokines, including interleukin-1 (IL-1), IL-6, and
TNF-a, in mouse macrophages [30]. Those cytokines are in-
volved in various pathological conditions such as atherosclero-
sis and hypertension [34], thus nobiletin may demonstrate a
suppressive ability at sites of chronic inﬂammation.
Other compelling evidence indicates that citrus ﬂavonoids,
including nobiletin, can suppress the hepatic production of
cholesterol-containing lipoproteins, thus reducing the total
cholesterol concentration in plasma-, and leading to a
reduction in the occurrence of cardiovascular disease [35,36].
Nobiletin has been shown to have a hepatic apolipoprotein
B-lowering potential in vitro [36,37], while recent results sug-
gested that it can reduce the circulating concentrations of very
low density lipoproteins and LDL in blood, and directly inhi-
bit macrophage-derived foam cell formation at the site of le-
sion development within vessel walls [38,39]. Whitman et al.
showed that nobiletin reduced the accumulation of cholesterol
ester mediated by acLDL (a known ligand for SR-A) in the
mouse macrophage line J774A [39]. Therefore, it is possible
that nobiletin inhibits the process of acLDL internalization
mediated by SR-A, though it did not show an eﬀect toward to-
tal and surface SR-A protein expression levels [39]. The action
mechanisms underlying the anti-atherogenic eﬀects of nobiletin
described above remain to be clariﬁed.
In the present study, we showed for the ﬁrst time that nobi-
letin suppresses the expression of multiple SR and adhesion
molecule genes induced by phorbol ester, such as that of
LOX-1, SR-A, SR-PSOX, CD68, CD36, CD11b, and CD18.
The relevance of suppression of their expression by nobiletin
in vitro in the process of preventing the initiation and progres-
sion of atherosclerosis in vivo remains unclear. Tsukamoto
et al. analyzed the expressions of SRs at diﬀerent stages of dif-
ferentiation from THP-1 monocytes to foam cells, and their re-
sults suggested that CD36, CLA-1, and CD68, but not SR-A
or LOX-1, play crucial roles in the progression to foam cells
from macrophages [40]. We believe that our results also pro-
vide insight into the molecular mechanisms, whose under-
standing is necessary to explain the anti-atherogenic actions
of this ﬂavonoid.Treatment of THP-1 cells with TPA induces a program of
macrophage diﬀerentiation and marked upregulation of SR
genes [41]. The 5 0 ﬂanking region of the human LOX-1 gene
contains multiple putative binding sites for several transcrip-
tion factors, including those of AP-1, GATA family, STAT
family, NF-IL6, Oct-1, CCAAT enhancer-binding proteins,
and cyclic AMP response element binding protein [27]. Protein
kinase C activated by TPA is known to stimulate the activities
of several classes of transcription factors, including AP-1 [42].
The present results suggest that the inhibitory eﬀects of nobile-
tin toward TPA-induced LOX-1 expression are partly associ-
ated with the suppression of AP-1 activity (Fig. 1C). This
notion is supported by several previous ﬁndings, while we re-
cently found that nobiletin downregulates MMP-7 expression
in HT-29 human colorectal cancer cells via a reduction in
AP-1 DNA binding activity [32]. Along a similar line, Sato
et al. demonstrated that nobiletin inhibits the invasive activity
of TPA stimulated-human ﬁbrosarcoma HT-1080 cells by sup-
pressing AP-1 binding activity [30].
AP-1 transcriptional activity is dependent on both ERK1/2
and JNK1/2 MAPK-mediated signaling pathways for c-Fos
and c-Jun induction, as well as c-Jun phosphorylation. In the
present study, nobiletin inhibited the phosphorylation of
JNK1/2 (Fig. 2A), which presumably results in decreased
JNK1/2 activity, leading to a reduced level of c-Jun phosphor-
ylation and blocking of AP-1 transcription activity. Previous
reports have shown that ERK1/2 activation contributes to
AP-1 activation by Elk-1 phosphorylation, which induces c-
Fos synthesis. Although nobiletin inhibited the phosphoryla-
tion of ERK1/2, c-Fos protein levels did not change within
6 h. Thus, it remains unclear whether ERK1/2 repression by
nobiletin plays a role in AP-1 activation.
Nobiletin is a hydrophobic molecule that has six methoxyl
groups, which is a characteristic associated with a high cellular
uptake rate in vitro as compared with general ﬂavonoids [43].
In an in vivo study as well, we showed that nobiletin exhibits
greater localization in the mucosa and muscularis in the gas-
trointestinal tract as compared to luteolin, a ﬂavonoid with
four hydroxyl groups [44]. Thus, it is important to examine
the ability of nobiletin to absorb into and localize within blood
vessel walls.
In conclusion, we found that nobiletin has a distinct ability
to suppress the expression of multiple SRs induced by TPA via
AP-1 repression, which blockaded DiI-acLDL uptake. Our re-
sults suggest that this ﬂavonoid may be eﬀective as an agent to
regulate the development of atherosclerosis. Further studies
utilizing atherosclerosis-prone animal models are needed to
clarify our ﬁndings.
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